Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ophiopogonin-D 通过 RIPK1 显着抑制前列腺细胞的体外和体内生长,OPD 可能被开发为潜在的抗前列腺癌药物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 621 | 现货 | ||
5 mg | ¥ 1,530 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,520 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 7,230 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,130 | 现货 |
产品描述 | Ophiopogonin-D significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1. Ophiopogonin-D may be developed as a potential anti-prostate cancer agent. |
体外活性 | Ophiopogonin D(OPD) was shown to exert potent anti-tumor activity against PC3 cells.?It induced apoptosis via a RIPK1-related pathway, increased the protein expression levels of RIPK1 and Bim, and decreased the levels of cleaved-RIPK1, caspase 8, cleaved-caspase 8, Bid, caspase 10, and cleaved-caspase 10.?OPD' also increased the mRNA expression of Bim.?The protein expression of Bim was decreased when cells were pre-treated with necrostatin-1[1]. |
体内活性 | Ophiopogonin D(OPD)′ treatment led to significant tumor growth inhibition at a dose of 5.0 mg/kg bodyweight, beginning on Day 6 of treatment (p = 0.034).?At the end of the study (Day 24), the tumor tissues were excised, photographed, and weighed.?Treatment with 5.0 mg/kg bodyweight OPD′ resulted in significant (p = 0.000) tumor growth inhibition by approximately 79.8% on Day 24 compared to the vehicle treatment.?The 5.0 mg/kg dose led to significantly stronger tumor growth inhibition than the 2.5 mg/kg dose (p = 0.000).?There was not a significant loss of body weight in any of the groups[1]. |
细胞实验 | The CCK-8 assay was used to assess the viability of prostate cancer cells.?The cell morphology was examined by an ultrastructural analysis via transmission electron microscopy.?Cells in apoptosis (early and late stages) were detected using an Annexin V-FITC/propidium iodide kit with a FACSCaliber flow cytometer.?JC-1, a cationic lipophilic probe, was employed to measure the mitochondrial membrane potential (MMP) of PC3 cells.?Changes in the protein expression of RIPK1, C-RIPK1, caspase 8, cleaved-caspase 8, Bim, Bid, caspase 10, and cleaved-caspase 10 were evaluated by Western blotting.?The mRNA expression of Bim was examined by quantitative real-time reverse transcription polymerase chain reaction.?Z-VAD-FMK (a caspase inhibitor) and necrostatin-1 (a specific inhibitor of RIPK1) were utilized to determine whether the cell death was mediated by RIPK1 or caspases[1]. |
动物实验 | One week after tumor cell inoculation, mice bearing palpable tumors were randomly divided into control and treatment groups (8 mice/group).?OPD′ was dissolved in the vehicle, PEG400:Saline:Ethanol (400:300:200, v/v/v), and administered (via i.p. injection) at doses of 2.5 or 5.0 mg/kg bodyweight 5 days a week for 24 days.?The control group received vehicle only.?The mice were sacrificed by cervical dislocation on Day 24, and the tumor tissues were removed and weighed[1]. |
别名 | 麦冬皂苷D |
分子量 | 855.02 |
分子式 | C44H70O16 |
CAS No. | 41753-55-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (35.09 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1696 mL | 5.8478 mL | 11.6956 mL | 29.2391 mL |
5 mM | 0.2339 mL | 1.1696 mL | 2.3391 mL | 5.8478 mL | |
10 mM | 0.117 mL | 0.5848 mL | 1.1696 mL | 2.9239 mL | |
20 mM | 0.0585 mL | 0.2924 mL | 0.5848 mL | 1.462 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ophiopogonin-D 41753-55-3 Immunology/Inflammation ROS Ophiopogonin D 麦冬皂苷D OphiopogoninD Inhibitor inhibitor inhibit